论文部分内容阅读
目的 研究重组人可溶性血管内皮细胞生长抑制因子 (VEGI)对小鼠异体种植 S- 180肉瘤生长的抑制作用。 方法 用不同剂量 VEGI分别治疗皮下和腹腔种植 S- 180肉瘤的小鼠 ,连续 7天。 30天后处死小鼠 ,剥离肿瘤并称重 ,计算每组平均瘤重和抑瘤率 ;记录腹腔种植组小鼠的死亡时间 ,观察治疗制剂对小鼠寿命的影响。采用免疫组织化学 Envision二步法对肿瘤组织进行分析。 结果 VEGI治疗组 (5 .0 ,10 .0 ,2 0 .0μg/ kg)的平均瘤重分别为 2 .92± 2 .0 5 g,1.92± 0 .31g和 1.0 6± 0 .0 5 g,明显小于 PBS对照组 (10 .33± 2 .15 g,P<0 .0 1) ,抑瘤率分别为 71.73% ,81.41%和 89.74% ;并可明显延长腹腔荷 S- 180肉瘤小鼠的生存时间 (P<0 .0 1)。每 mm2 肿瘤组织切片中 ,VEGI治疗组 (10 .0μg/ kg)的阳性血管内皮细胞数为 117± 10个 ,PBS对照组 2 41± 34个 (P<0 .0 5 )。 结论 VEGI通过抑制体内肿瘤组织中血管的生成抑制了恶性肿瘤的生长 ,显示出显著的抗肿瘤活性。
Objective To study the inhibitory effect of recombinant human soluble vascular endothelial growth inhibitory factor (VEGI) on the growth of allogeneic S-180 sarcoma in mice. Methods The mice with S-180 sarcoma implanted subcutaneously and intraperitoneally were treated with different doses of VEGI for 7 consecutive days. After 30 days, the mice were sacrificed and the tumors were dissected and weighed to calculate the average tumor weight and the tumor inhibition rate. The death time of the mice in the intraperitoneal implantation group was recorded, and the effect of the therapeutic preparations on the life span of the mice was observed. Tumor tissue was analyzed by immunohistochemistry Envision two-step method. Results The mean tumor weights of VEGI group (5.0, 10.0, 2.0 μg / kg) were 2.92 ± 2.05 g, 1.92 ± 0.31 g and 1.0 6 ± 0. 05 g , Which was significantly lower than PBS control group (10.33 ± 2.15g, P <0.01). The tumor inhibition rates were 71.73%, 81.41% and 89.74%, respectively. Survival time (P <0.01). Per mm2 tumor tissue sections, the number of positive vascular endothelial cells in VEGI-treated group (10 .0 μg / kg) was 117 ± 10 and in PBS control group was 41 ± 34 (P <0.05). Conclusion VEGI inhibits the growth of malignant tumors by inhibiting the formation of blood vessels in tumor tissues and shows significant anti-tumor activity.